eGFR

What eGFR Measures

eGFR estimates the volume of blood your kidneys filter per minute, normalized for body surface area. Calculated from serum creatinine plus age, sex, and (in some equations) race. The CKD-EPI 2021 equation removed the race coefficient and is now standard.

eGFR declines naturally with age - about 1 mL/min/1.73m² per year after age 30. Persistent eGFR <60 for >3 months meets the definition of chronic kidney disease (CKD) regardless of cause.

What Affects This Biomarker

eGFR is influenced by: kidney function (the actual measurement target), age (declines with), muscle mass (high muscle = higher creatinine = lower estimated eGFR - equation may underestimate kidney function in muscular individuals - Cystatin C is better for this), hydration status (acute changes), recent meat intake (small bump in creatinine), and pharmacologic agents - NSAIDs lower; ACE inhibitors and ARBs cause initial small drop then stabilize; SGLT2 inhibitors cause early dip then preservation; metformin and many drugs require dose adjustment based on eGFR.

In the Context of Peptide Protocols

Track baseline + annually. Particularly important for users on metformin (eGFR <30 = stop), GLP-1s (mostly safe across eGFR), and any nephrotoxic compound. On long-term high-protein diets or peptide users with high lean mass, consider Cystatin C-based eGFR for more accurate estimate. Significant drops warrant nephrology workup.

Deep Dive

eGFR is an estimate, not a measurement

The "e" in eGFR does a lot of quiet work. Your kidneys' true filtration rate can only be measured directly with an infused tracer such as iohexol or inulin, which is slow and impractical. Instead, eGFR is a regression equation that back-calculates filtration from **serum creatinine**, a byproduct of muscle metabolism, plus age and sex. That means the number inherits every quirk of creatinine.

The relationship also is not linear. Filtration is roughly inversely proportional to creatinine, so a **doubling of creatinine corresponds to roughly a halving of GFR**. At the low-creatinine, high-filtration end of the scale where healthy people live, a tiny shift in creatinine swings eGFR by many points. This is why the estimate is least precise exactly where most optimizers sit, above 60, and why many labs simply report ">90" or ">60" rather than a sharp figure up there.

A useful accuracy benchmark is **P30**, the fraction of estimates that land within 30 percent of a directly measured GFR. Modern CKD-EPI equations achieve roughly 85 to 90 percent P30, which is strong for an equation but still means a single reading can be off by 10 to 20 points. Treat one eGFR as a data point, not a verdict, and watch the trend across draws.

Why a higher number is not automatically better

The page's optimal target of above 90 holds for most adults, but eGFR is one of the few biomarkers where climbing well past normal can be a warning rather than reassurance. When eGFR runs unusually high, often above roughly 130 to 140, it can reflect **glomerular hyperfiltration**, an early stress response in which each nephron overworks. Hyperfiltration is well documented in early diabetes, obesity, sustained very high protein intake, and pregnancy, and it can precede a decline in filtration by years.

The practical takeaway is that population mortality risk plotted against eGFR tends to be **U-shaped**: risk is elevated at low values, as expected, but also creeps up at supra-normal values driven by hyperfiltration. A rising number is not something to celebrate on its own. Context, especially metabolic status, is what tells you whether a high reading is robust reserve or an overworked kidney.

eGFR alone undersells kidney risk: pair it with albuminuria

Filtration rate is only one of two axes clinicians use. The **KDIGO** framework stages kidney health on a grid: a GFR category (G1 through G5) crossed with an **albuminuria category** (A1 through A3), measured as the urine albumin-to-creatinine ratio (UACR). What the research shows repeatedly is that **albuminuria often rises before eGFR falls**, particularly in metabolic and diabetic kidney disease. Small amounts of albumin leaking into urine flag glomerular injury while filtration still looks pristine.

That is why a person can have a perfectly normal eGFR above 90 and still meet the definition of chronic kidney disease if UACR is elevated. If you only ever track eGFR, you are watching the slower of the two hands on the clock. Pulling a UACR alongside eGFR gives a far earlier and more complete read, and it is a cheap urine test.

Testing pitfalls that move creatinine without moving your kidneys

Because eGFR is built on creatinine, anything that shifts creatinine independent of true filtration will distort the estimate. Common non-kidney movers to standardize before a draw:

- **Creatine supplementation** can raise serum creatinine by roughly 0.1 to 0.2 mg/dL (sometimes more at high loading doses), mechanically lowering eGFR with no change in filtration. - **A large red-meat meal** in the prior 12 hours transiently bumps creatinine. - **Intense resistance or endurance training** in the 24 to 48 hours before testing can elevate creatinine. - **Dehydration** acutely reduces filtration and inflates creatinine.

A subtler trap is drug interference with tubular secretion. **Trimethoprim and cimetidine** block the kidney tubule's secretion of creatinine, so serum creatinine rises and eGFR drops even though true GFR has not changed. This pseudo-decline reverses when the drug stops. Separately, the initial eGFR dip after starting an ACE inhibitor, ARB, or SGLT2 inhibitor is **hemodynamic**, not injury: it reflects reduced pressure inside the glomerulus, and a creatinine rise up to about 30 percent is generally expected and tolerated. Confirm any change is sustained beyond three months, under standardized conditions, before reading meaning into it.

What the research shows about the trajectory, and how to track it

Several interventions have strong trial evidence for slowing eGFR decline over time. SGLT2 inhibitors slowed loss of kidney function in landmark trials including **DAPA-CKD** (dapagliflozin), **CREDENCE** (canagliflozin), and **EMPA-KIDNEY** (empagliflozin), each showing an early dip followed by long-term preservation. On the GLP-1 side, the **FLOW trial** (semaglutide, published 2024) reduced progression of kidney disease in people with type 2 diabetes and existing CKD. Blood pressure and glycemic control remain the durable background levers the guidelines emphasize.

For MyProtocolStack users, the most important tracking nuance is confounding from body composition. High lean mass from **TRT, growth hormone peptides, or IGF-1 protocols**, plus creatine use, elevates creatinine and can make the creatinine-based estimate read artificially low without any real dysfunction. When creatinine and eGFR look confusing in a muscular person, a **cystatin C-based or combined creatinine-cystatin C eGFR** (the CKD-EPI 2021 equations from Inker and colleagues) is more accurate, though cystatin C itself is nudged by inflammation, corticosteroids, thyroid status, and adiposity. The durable habit is to log a baseline, follow the trend rather than any single value, and pair eGFR with UACR and, when relevant, cystatin C. Bring meaningful or sustained changes to your clinician rather than self-interpreting a one-off reading.

Frequently Asked Questions

Where This Fits in Your Panel

eGFR is one marker on a fuller panel. The Peptide Blood Work Checklist lays out the complete baseline panel, what to add by protocol type, and when to retest.

Upload any lab PDF and MyProtocolStack maps your values to eGFR and 40+ other biomarkers. StackAI interprets the trend in context of your protocol.